Beam Therapeutics, Inc. (BEAM)

In the past six months, Beam Therapeutics' stock has experienced significant movements. In January 2026, the stock price increased substantially following positive updates regarding its alignment with the FDA on its sickle cell therapy risto-cel and BEAM-302. Analyst ratings have varied, with UBS initiating coverage at "Neutral," Bernstein SocGen Group raising its price target, and HC Wainwright reaffirming a "buy" rating. Beam ended 2025 with $1.25 billion in cash, extending its operating runway into 2029.

As a biotechnology company with products in clinical development, Beam Therapeutics does not experience direct demand seasonality for its products and services. However, historical stock data suggests that buying Beam Therapeutics Inc. (BEAM) stock in June has the highest probability of a positive return, while March has the lowest probability.

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its base editing technology. The company aims to provide lifelong cures for serious diseases through precise and efficient DNA base changes. Beam's pipeline includes therapies like BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency (AATD), BEAM-301 for glycogen storage disease 1a (GSD1a), BEAM-201 (an anti-CD7 CAR-T product candidate), BEAM-103 and BEAM-104 for sickle cell disease and beta-thalassemia, and ESCAPE for HSC transplantation. The company collaborates with other pharmaceutical companies to advance its gene editing programs.

Beam Therapeutics Inc. is headquartered in Cambridge, Massachusetts, and primarily operates and manages its business in the United States.

Beam Therapeutics' brand reputation has been positively influenced by its clinical progress and regulatory interactions, particularly its alignment with the FDA on accelerated approval pathways and inclusion in the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program. Participation in industry conferences also contributes to its brand reputation.

Beam Therapeutics Inc. has a substantial base of institutional ownership, with 451 institutional owners holding approximately 87.6% to 91.03% of the company's shares. Major institutional owners include Fmr Llc, ARK Investment Management LLC, and Vanguard Group Inc. Individual investors hold approximately 1.6% of the shares, while insiders hold about 13.64%, with Fmr LLC being the largest individual shareholder. Insider activity in the past year has shown more selling than buying.